Citation Impact
Citing Papers
Effect of Clopidogrel Added to Aspirin in Patients with Atrial Fibrillation
2009 Standout
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
2014 Standout
Randomized Trial of Genotype-Guided Versus Standard Warfarin Dosing in Patients Initiating Oral Anticoagulation
2007
Recent Advances in Breast Cancer-Related Lymphedema of the Arm: Lymphatic Pump Failure and Predisposing Factors
2009
Major bleeding during secondary prevention of venous thromboembolism in patients who have completed anticoagulation: a systematic review and meta‐analysis
2014
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
2013 Standout
Aspirin for Preventing the Recurrence of Venous Thromboembolism
2012
Antithrombotic Therapy for Venous Thromboembolic Disease
2008 Standout
Pharmacology and Management of the Vitamin K Antagonists
2008 Standout
Mechanisms of Thrombus Formation
2008 Standout
Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta‐analysis
2011
Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients
2009
Universal Definition of Myocardial Infarction
2007 Standout
A C1173T Dimorphism in the VKORC1 Gene Determines Coumarin Sensitivity and Bleeding Risk
2005
Genetic effects on gene expression across human tissues
2017 StandoutNature
Intracerebral haemorrhage
2009 Standout
Evidence-Based Management of Anticoagulant Therapy
2012
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation
2005
Apixaban for Extended Treatment of Venous Thromboembolism
2012
Risk of Recurrent Venous Thromboembolism in Patients With Common Thrombophilia
2006
Oral Anticoagulant Therapy
2012 Standout
National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: Clinical Characteristics and Utilization of Biochemical Markers in Acute Coronary Syndromes
2007
Lymphangiogenesis: Molecular Mechanisms and Future Promise
2010 Standout
Antithrombotic Therapy for VTE Disease
2016 Standout
Intracranial and fatal bleeding according to indication for long‐term oral anticoagulant therapy
2010
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
2003 Standout
Combined genetic profiles of components and regulators of the vitamin K-dependent γ-carboxylation system affect individual sensitivity to warfarin
2006
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
Extended Use of Dabigatran, Warfarin, or Placebo in Venous Thromboembolism
2013
Unresolved issues in anticoagulant therapy
2003
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
2014 Standout
Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes
2010
Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy
2008
The Influence of Patient Adherence on Anticoagulation Control With Warfarin
2007
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Treatment of Deep-Vein Thrombosis
2004
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis
2013
A Prospective Natural-History Study of Coronary Atherosclerosis
2011 Standout
Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention
2014
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
2013 Standout
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
2009 Standout
Antithrombotic Therapy for VTE Disease
2012 Standout
Platelet Activation and Atherothrombosis
2007 Standout
CYP2C9 Genotype-guided Warfarin Prescribing Enhances the Efficacy and Safety of Anticoagulation: A Prospective Randomized Controlled Study
2007
Warfarin and its interactions with foods, herbs and other dietary supplements
2006
Pharmacogenomics: Challenges and Opportunities
2006
Genetic and clinical factors relating to warfarin dosing
2009
Influence of preceding length of anticoagulant treatment and initial presentation of venous thromboembolism on risk of recurrence after stopping treatment: analysis of individual participants' data from seven trials
2011
Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of Warfarin
2008
The Missing Diversity in Human Genetic Studies
2019 Standout
Common VKORC1 and GGCX polymorphisms associated with warfarin dose
2005
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
2009 Standout
10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes
2008 Standout
Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue
2011
A genotyping method for VKORC1 1173C>T by Pyrosequencing®technology
2008 StandoutNobel
Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases
2018 Standout
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
2008 Standout
Predictive Value of Factor V Leiden and Prothrombin G20210A in Adults With Venous Thromboembolism and in Family Members of Those With a Mutation
2009
Several-fold increase in risk of overanticoagulation by CYP2C9 mutations
2005
Comparison of Low-Intensity Warfarin Therapy with Conventional-Intensity Warfarin Therapy for Long-Term Prevention of Recurrent Venous Thromboembolism
2003
Secondary Prevention of Venous Thromboembolism with the Oral Direct Thrombin Inhibitor Ximelagatran
2003
The Pharmacology and Management of the Vitamin K Antagonists
2004 Standout
Pulmonary thrombosis in adults with Eisenmenger syndrome
2003
Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment
2008
A genome-wide association study of acenocoumarol maintenance dosage
2009
Warfarin-Induced Skin Necrosis and Venous Limb Gangrene in the Setting of Heparin-Induced Thrombocytopenia
2004
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy
2009
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
2013 Standout
The Current State of Knowledge on Age, Sex, and Their Interactions on Clinical Pharmacology
2007
Individual time within target range in patients treated with vitamin K antagonists: main determinant of quality of anticoagulation and predictor of clinical outcome. a retrospective study of 2300 consecutive patients with venous thromboembolism
2005
Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis
2015 Standout
D‐dimer, factor VIII coagulant activity, low‐intensity warfarin and the risk of recurrent venous thromboembolism
2006
Influence of CYP2C9 genotype on warfarin dose requirements—a systematic review and meta-analysis
2008
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
2006
Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records
2006 StandoutNobel
Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF)
2006
Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal
2004
Hemorrhagic Complications of Anticoagulant Treatment
2004
Oral Apixaban for the Treatment of Acute Venous Thromboembolism
2013 Standout
Antithrombotic Therapy for Venous Thromboembolic Disease
2004 Standout
Effect of Blood Pressure Lowering and Antihypertensive Drug Class on Progression of Hypertensive Kidney Disease<SUBTITLE>Results From the AASK Trial</SUBTITLE>
2002 Standout
Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population
2005
Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials
2003 Standout
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
2017 Standout
Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects
2004
Serpin Structure, Mechanism, and Function
2002 Standout
Influence of CYP2C9 and VKORC1 on Warfarin Dose, Anticoagulation Attainment and Maintenance Among European–Americans and African–Americans
2008
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon
2008
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
2010 Standout
Duration of anticoagulation following venous thromboembolism: a meta-analysis.
2005
The influence of sequence variations in factor VII, γ-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement
2006
Prothrombotic phenotype of protein Z deficiency
2000
The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
2015 Standout
The Genetic Architecture of Intracerebral Hemorrhage
2008
Guidelines for Prevention of Stroke in Patients With Ischemic Stroke or Transient Ischemic Attack
2006 Standout
Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension
2011 Standout
Influence of thrombophilia on risk of recurrent venous thromboembolism while on warfarin: results from a randomized trial
2008
ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease
2006 Standout
Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data
2009
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics‐Guided Warfarin Dosing: 2017 Update
2017
Low-Molecular-Weight Heparin Compared with Intravenous Unfractionated Heparin for Treatment of Pulmonary Embolism
2004
Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis.
2003
Residual Thrombosis on Ultrasonography to Guide the Duration of Anticoagulation in Patients With Deep Venous Thrombosis
2009
2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation
2014 Standout
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Iron Supplementation in Nephrology and Oncology: What Do We Have in Common?
2011
Extended Prophylaxis of Venous Thromboembolism with Idraparinux
2007
CYP2C9*8 is Prevalent Among African–Americans: Implications for Pharmacogenetic Dosing
2009
Iron-Deficiency Anemia
2015 Standout
Use and Effectiveness of Warfarin in Medicare Beneficiaries With Atrial Fibrillation
2006
Warfarin and Heparin-Induced Skin Necrosis and the Purple Toe Syndrome: Infrequent Complications of Anticoagulant Treatment
1997
2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
2013 Standout
Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis
2006
Guidelines for the Prevention of Stroke in Patients With Stroke or Transient Ischemic Attack
2010 Standout
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
2006 Standout
Predictive Value of D-Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia
2003
Duration of treatment with vitamin K antagonists in symptomatic venous thromboembolism
2014
Biomarkers of Cardiovascular Disease
2006
Systematic Review: Case-Fatality Rates of Recurrent Venous Thromboembolism and Major Bleeding Events Among Patients Treated for Venous Thromboembolism
2010
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
A novel sequence variant in exon 7 of CYP2C9 gene (CYP2C9*24) ina patient on warfarin therapy
2006
Works of Charles S. Eby being referenced
Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism
2003
Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design
2011
Intra-individual variability in serum hepcidin precludes its use as a marker of iron status in hemodialysis patients
2010
Effect of VKORC1 Haplotypes on Transcriptional Regulation and Warfarin Dose
2005
Ischemia-modified albumin increases after skeletal muscle ischemia during arthroscopic knee surgery
2005
Pharmacogenetics and Anticoagulant Therapy
2003
Soluble CD40 Ligand Measurement Inaccuracies Attributable to Specimen Type, Processing Time, and ELISA Method
2005
Lymphangiosarcoma: A Lethal Complication of Chronic Lymphedema
1967
Warfarin-Induced Skin Necrosis
1993